Published in Medical Letter on the CDC and FDA, April 18th, 2010
Mr. Leonhardt stated, "Today I am increasing my investment stake in Bioheart by $2 million due to my great confidence in the future of the company. I feel that Bioheart's current stock price does not reflect its potential. The strides that the Company has made to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.